ArticleNature communications2026
Proteomic characterization of intrahepatic cholangiocarcinoma identifies risk-stratifying subgroups and EIF4A1 as a therapeutic target.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Proteomic characterization of intrahepatic cholangiocarcinoma identifies risk-stratifying subgroups and EIF4A1 as a therapeutic target.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Intrahepatic cholangiocarcinoma (ICC) features poor survival due to frequent recurrences and limited prognostic markers. Using mass spectrometry-based proteomics, we analyze two independent cohorts comprising 80 and 62 treatment-naive ICC tumors, along with 9 independent patient-derived xenografts (PDX). In the first cohort, we identify two subclusters with distinct times-to-recurrence (TTR): An extracellular matrix (ECM)-enriched cluster (mean TTR 859 days) and a proliferation cluster (mean TTR 229 days). A 4-protein classifier trained on our cohort accurately stratifies these clusters in the Dong et al. dataset (2022) and in our second cohort, revealing similar proteomic motifs and clinical outcomes. The translation regulator EIF4A1, enriched in ICCs of both clusters, emerges as a therapeutic target, as its inhibition with eFT226 significantly reduces tumor growth in an ICC PDX model. Proteomic analyses of various PDX models also emphasize the critical role of tumor-stroma interactions in ICC. Overall, this study establishes two prognostic proteomic clusters, validates their relevance across datasets, and highlights EIF4A1 inhibition as a potential therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.